Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other 1NET 1Endocrine 1Dermatologic 1Breast 1

Conditions

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1

Interventions

Injections 54pembrolizumab 40Carboplatin 20Bevacizumab 19Cyclophosphamide 17toripalimab 14Nivolumab 14Cisplatin 14tislelizumab 13fludarabine 13Specimen Handling 13Paclitaxel 13Interviews as Topic 13Pemetrexed 12Standard of Care 11Practice Guidelines as Topic 11Oxaliplatin 11Fluorouracil 10Cetuximab 10atezolizumab 9Educational Status 9Docetaxel 9Capecitabine 9Leucovorin 8Methods 7Etoposide 7Early Intervention, Educational 7spartalizumab 6olaparib 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leflunomide × Other solid neoplasm × Clear all
NCT04997993 2025-06-25

Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies and HER2 Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Recruiting
24 enrolled
BreastOther solid neoplasm

PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡